- Home
- ACIC vs ASMB Comparison
ACIC vs ASMB Comparison
Compare ACIC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ASMB |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 442.9M |
| IPO Year | 2007 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ASMB |
|---|---|---|
| Price | $10.15 | $26.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 297.9K | 245.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | 39.61 | ★ 91.78 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | $638.39 |
| P/E Ratio | $27.72 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.80 | $16.90 |
| 52 Week High | $13.06 | $39.71 |
Technical Indicators
Market Signals| Indicator | ACIC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 50.41 |
| Support Level | $9.80 | $26.18 |
| Resistance Level | $11.52 | $30.68 |
| Average True Range (ATR) | 0.35 | 1.46 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 1.89 | 46.08 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.